Phase 3 Type 2 Diabetes Trial, Recruiting
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- Women who have gone through menopause and are aged 65 years or older
- People who have been diagnosed with type 2 diabetes
- People with a Body Mass Index (BMI) between 27 and 40 (inclusive)
- People whose blood sugar control measure (HbA1c) was between 7% and 10% within the 3 months before their first visit
- People who are willing and able to follow all study procedures, including fasting requirements at certain visits
- People who have had a bone density scan (DEXA scan) within the last 12 months confirming they do not have osteoporosis
- People who are able to give informed consent and take part in all study assessments
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People who have type 1 diabetes, or any form of diabetes other than type 2
- People whose kidney function test (eGFR) result was below 30 ml/min in the last 3 months
- People who have previously been treated with medications used to prevent or treat osteoporosis
- People whose bone density scan (DEXA scan) within the last 12 months showed primary or secondary osteoporosis, or who are currently taking osteoporosis medications
- People who have an artificial joint, implant, or medical device in their spine or hip
- People who have previously had a fragility fracture (a bone break caused by a minor injury due to weaker bones)
- Men
- People with moderate to severe gastroesophageal reflux disease (persistent, significant heartburn or acid reflux) based on their medical history
- People who are unable to follow the treatment protocol or understand the consent form
- People whose liver enzyme levels (AST or ALT) are more than 3 times the normal range
- People with an uncontrolled thyroid or parathyroid condition that could affect the study results
- People with a personal or family history of a specific type of thyroid cancer called medullary thyroid carcinoma
- People with a personal or family history of a condition called multiple endocrine neoplasia type 2 syndrome
- People with a personal history of any of the following conditions: delayed stomach emptying (gastroparesis), celiac disease, low sex hormone levels (hypogonadism), severe chronic obstructive pulmonary disease (COPD), underactive pituitary gland (hypopituitarism), or Cushing's disease
- People with a personal history of severe diabetic eye disease (severe diabetic retinopathy)
- People who have had a serious allergic reaction, including anaphylaxis or severe swelling (angioedema), to semaglutide or any of its ingredients
- People who have used any of the following medications in the 6 months before screening: GLP-1 receptor agonists, GIP analogues, pioglitazone, or DPP-4 inhibitors
- People who are currently being treated with a GLP-1 receptor agonist medication
- People who have used high-dose corticosteroids (taken by mouth, injection into a vein, or injection into a joint) for more than 7 days in a row within the 2 months before screening
- People who have used weight-loss medications or had weight-loss surgery in the 6 months before screening, or who are currently following an active weight-loss plan rather than a weight maintenance plan
- People who are currently incarcerated
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Thaer Idrees, MD, FSSCI, Emory University
Phone: 404-251-5357
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Change in handgrip strength
Can't join this trial?
Data last synced from ClinicalTrials.gov: 31 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.